Biolase (BIOL) Misses Q4 EPS by 2c

Biolase (NASDAQ: BIOL) reported Q4 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.9 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Benchmark Reiterates Buy Rating on Jumia Technologies (JMIA)